Prenetics Global Limited: Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220-230 Million; July Was the First Month of Positive Consolidated Adjusted
Prenetics Global (NASDAQ: PRE) reported Q2 2026 revenue of $46.5 million, up about 288% YoY, and IM8 revenue of $45.0 million, up about 359% YoY. Results were within guidance. The company raised FY 2026 total revenue guidance to $220-230 million and initiated FY 2027 IM8 revenue guidance of $400 million+.
How this was made
The 30-second read
Why it matters
The key trading driver is the combination of Q2 outperformance versus guidance ranges and a raised FY2026 revenue outlook, plus initiation of FY2027 IM8 revenue guidance at $400M+.
Market read
A same-day earnings release with explicit guidance raises and new FY2027 IM8 revenue targets is likely to drive estimate revisions and near-term positioning in PRE.
What to watch
The release notes a Customer Investment Agreement with GC Customer Value Arranger, LLC and other forward-looking risks; traders may scrutinize whether financing or customer investment dynamics are supporting growth.
Background
Prenetics’ IM8 is positioned as an AI-native direct-to-consumer wellness brand; this quarter marks a shift to more detailed shareholder materials and a live earnings stream.
Ticker impact
Prenetics reported Q2 2026 revenue of $46.5M (+288% YoY) and raised FY 2026 total revenue guidance to $220-$230M.
Likely positive reaction and higher probability of upward estimate revisions, especially if investors focus on the new FY2026 and FY2027 IM8 guidance.
The article discloses fresh, decision-relevant datapoints: Q2 results, raised FY2026 guidance, and initiated FY2027 IM8 revenue guidance of $400M+.
Market effects
Consumer health and DTC wellness investors may re-rate growth expectations for AI-native supplement brands if PRE’s cohort economics and card data support durability.
Limited, primarily US small/mid-cap growth sentiment tied to NASDAQ-listed PRE.
Moderate, as PRE highlights IM8 shipping to 46 countries and global run-rate momentum.
Counterpoint
The guidance jump could be driven by early-stage scale effects; investors may discount sustainability until cohort economics and third-party card data confirm retention and CAC efficiency.
Key entities
- companyPrenetics Global Limited
NASDAQ-listed parent of IM8 that reported Q2 2026 results and raised FY2026 guidance.
- brandIM8
Prenetics’ direct-to-consumer wellness brand; reported IM8 revenue growth and provided run-rate momentum.
- personDanny Yeung
CEO and co-founder of IM8, quoted on record quarter, positive consolidated adjusted free cash flow, and guidance changes.
